4. K. Tamura, M. Fukuoka, “Molecular target-based cancer therapy: tyrosine kinase inhibitors”, International Journal of Clinical Oncology (2003), 8: 207- 211.

(1)

1. G. Vlahovic, J. Crawford, “Activation of Tyrosine Kinases in Cancer”, The Oncologist (2003), 8: 531-538.

2. S. Ghosh, X-P. Liu, Y. Zheng, F.M. Uckun, “Rational Design of Potent and Selective EGFR Tyrosine Kinase Inhibitors as Anticancer Agents, ” Current Cancer Drug Targets (2001), 1: 129-140.

3. G.M. Pontieri, M. A. Russo, L. Frati, Capitolo 22, “Oncogeni”: 585-616, Patologia Generale (2008), III Ediz., PICCIN.

4. K. Tamura, M. Fukuoka, “Molecular target-based cancer therapy: tyrosine kinase inhibitors”, International Journal of Clinical Oncology (2003), 8: 207- 211.

5. Lee M. Ellis, “Epidermal growth factor receptor in tumor angiogenesis”, Hematology/Oncology Clinics of North America (2004), 18: 1007-1021.

6. S. Sebastian, J. Settleman, S.J. Reshkin, A. Azzariti, A. Bellizzi, A. Paradiso,

“The complexity of targeting EGFR signalling in cancer: From expression to turnover”, Biochimica et Biophysica Acta (2006), 1766: 120-139.

7. C. Boccaccio, P.M. Comoglio, “The HGF receptor family: unconventional signal transducers for invasive cell growth”, Genes To Cell (1996), 1: 347-354.

8. M.A. Lemmon, “Ligand-induced ErbB receptor dimerization”, Experimental Cell Reserch (2009), 315: 638-648.

9. R. Bianco, T. Gelardi, V. Damiano, F. Ciardiello, G. Tortora, “Rational bases

for the development of EGFR inhibitors for cancer treatment”, The International

Journal of Biochemistry & Cell Biology (2007), 39: 1416-1431.

(2)

10. R. Pérez-Soler, “HER1/EGFR Targeting: refining the strategy”, The Oncologist (2004), 9: 58-67.

11. M. Alimandi, A. Cama , R. Mariani-Costantini, L. Frati, “Oncogeni e fattori di crescita tirosinchinasici”, Il Cancro: ricerca e applicazioni cliniche, CNR, Le Scienze (1994), 41-48.

12. B.P. Ceresa, S.L. Schmid, “Regulation of signal transduction by endocytosis”, Current Opinion in Cell Biology (2000), 12: 204-210.

13. G. Carpenter, S. Cohen, “Epidermal growth factor”, Annual Review of Biochemistry (1979), 48: 193-216.

14. J. Baselga, “Epidermal growth factor receptor pathway inhibitors”, Update on Cancer Therapeutics (2006) I: 299-310.

15. R.S. Herbst, “Targeting the epidermal growth factor receptor in cancer therapy”, Expert Opinion on Investigational Drugs (2002), 11: 837-849.

16. M.L. Janmaat, G. Giaccone, “Small-Molecule Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors”, The Oncologist (2003), 8: 576-586.

17. R.L. Comis, “The current situation: Erlotinib (Tarceva

^®

) and Gefitinib (Iressa

^®

) in Non-Small Cell Lung Cancer”, The Oncologist (2005), 10: 467-470.

18. D.W. Rusnak, K. Lackey, K. Afflek, E.R. Wood, K.J. Alligood, N. Rhodes, B.

Keith, D.M. Murray, R.J. Mullin, W.B. Knight, T.M. Gilmer, “The Effects of

the Novel Reversible Epidermal Growth Factor Receptor/ErbB-2 Tyrosine

Kinase Inhibitor GW572016, on the Growth of Human Normal and Tumor

derived Cell Lines in Vitro and in Vivo”, Molecular Cancer Therapeutics

(2001), 1: 85.

(3)

19. S. Klein, A. Levitzki, “Targeting the EGFR and the PKB pathway in cancer”, Current Opinion in Cell Biology (2009), 21: 185–193.

20. J.B. Smaill, G.W. Rewcastle, J.A. Loo, K.D. Greis, O.H. Chan, E.L. Reyner, E.

Lipka, H.D. Showalter, P.W. Vincent, W.L. Elliott, W.A. Denny, “Tyrosine Kinase Inhibitors. Irreversible Inhibitors of the Epidermal Growth Factor Receptor: 4-(Phenylamino)-quinazoline and 4-(Phenylamino)pyrido[3,2- d]pyrimidine-6-acrylamides Bearing Additional Solubilizing Functions”, Journal of Medicinal Chemistry (2000), 43: 1380-1397.

21. M.A. Gieseg, C. De Bock, L.R. Ferguson, W.A. Denny, “Evidence for epidermal growth factor receptor-enhanced chemosensitivity in combination of cisplatin and new irreversible tyrosine kinase inhibitor CI-1033”, Anticancer Drugs (2001), 8: 683-90.

22. O. Dassonville, A. Bozec, J.L. Fischel, G. Milano, “EGFR Targeting Therapies:

Monoclonal antibodies versus tyrosine kinase inhibitors Similarities and difference”, Clical reviews in Oncology/Hematology (2007), 62: 53-61

23. B. Frederick, D. Gustafson, C. Bianco, F. Ciardiello, I. Dimery, D. Raben

“ZD6474, An inhibitor of VEGFR and EGFR tyrosine kinase activity in combination with radiotherapy”, International Journal of Radiation Oncology- Biology-Physics (2006), 64: 33–37.

24. A. Vulpetti, R. Bosotti. Sequence and structural analysis of kinase ATP pocket residues, Il Farmaco, (2004), 59: 759-765.

25. S. Trumpp-Kallmeyer, J. R. Rubin, C. Humblet, J.M. Hamby, H.D.H.

Showalter, “Development of Binding Model to Protein Tyrosine Kinases for

Substituted Pyrido[2,3-d]pyrimidine Inhibitors”, Journal of Medicinal

Chemistry, 41, 1752-1763 (1998).

(4)

26. B.D. Palmer, S. Trumpp-Kallmeyer, D.W. Fry, J.M. Nelson, H.D.H. Showalter, W.A. Denny, Tyrosine kinase inhibitors.11. Soluble Analogues of Pyrrolo and Pyrazoloquinazolines as Epidermal Growth Factor Receptor Inhibitors:

Synthesis, Biological Evaluation and Modeling of the mode of binding, Journal of Medicinal Chemistry, 40, 1519-1529 (1997).

27. Y. Graziani, E. Erikson, R. Erikson, “The effect of quercetin on the phosphorylation activity of the Rous sarcoma virus transforming gene product in vitro and in vivo”, European Journal of Biochemistry (1983), 135: 583-589.

28. T. Akiyama, J. Ishida, S. Nakagawa, H. Ogawara, S. Watanabe, N. Itoh, M.

Shibuya, Y. Fukami, “Genistein, a Specific Inhibitor of Tyrosine-specific Protein Kinases”, The Journal of Biological Chemistry (1987), 262: 5592-5595.

29. D.W. Fry, A.J. Kraker, A. McMichael, L.A. Ambroso, J.M. Nelson, W.R.

Leopold, R.W. Connors, A.J. Bridges, “A specific inhibitor of the epidermal growth factor receptor tyrosine kinase”, Science (1994), 265: 1093-1095.

30. A. J Barker, K.H. Gibson, W. Grundy, A.A. Godfrey, J.J. Barlow, M.P. Healy, J.R. Woodburn, S.E. Ashton, B.J. Curry, S. Lynn, L. Henthorn, L. Richards,

“Studies Leading to the Identification of ZD1839 (Iressa

^TM

): An Orally Active, Selective Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Targeted to the Treatment of Cancer”, Bioorganic & Medicinal Chemistry Letters (2001), 11: 1911–1914.

31. C. Wheeler, T. Stephens, K Byth, T. Green, S. Wedge, D. Blakey, A. Hughes,

“Novel approaches in oncology at AstraZeneca”, EJC Supplements (2003), 1: 3- 8.

32. G. W. Rewcastle, B.D. Palmer, A.M. Thompson, A.J. Bridges, D.R. Cody, H.

Zhou, D.W. Fry, A. McMichael, W.A. Denny, “Tyrosine Kinase Inhibitors. 10.

(5)

Binding Site Inhibitors of the Tyrosine Kinase Function of the Epidermal Growth Factor Receptor”, Journal of Medicinal Chemistry (1996), 36: 1823- 1835.

33. P. Traxler, F. Pascal, H. Mett, E. Buchdunger, T. Meyer, N. Lydon, “4- (Phenylamino)pyrrolopyrimidines: Potent and Selective, ATP Site Directed Inhibitors of the EGF-Receptor Protein Tyrosine Kinase”, Journal of Medicinal Chemistry (1996) 39 : 2285-2292.

34. P. Traxler, G. Bold, J. Frei, M. Lang, N. Lydon, H. Mett, E. Buchdunger, T.

Meyer, M. Mueller, P. Furet, “Use of pharmacophore model for the design of EGFR tyrosine kinase inhibitors: 4-(phenylamino)pyrazolo[3,4-d]pyrimidines”, Journal of Medicinal Chemistry (1997), 40: 3601-3616.

35. S. Schenone, O. Bruno, A. Ranise, F. Bondavalli, C. Brullo, P. Fossa, L. Mosti, G. Menozzi, F. Carraro, A. Naldini, C. Bernini, F. Manetti, M. Botta, “New pirazolo[3,4-d]pyrimidines endowed with A431 antiproliferative activity and inhibitory properties of Src phosphorylation”, Biorganic & Medicinal Chemistry Letters (2004), 14: 2511-2517.

36. C.N. Cavasotto, M.A. Ortiz, R.A. Abagyan, F.J. Piedrafita, “In silico identification of novel EGFR inhibitors with antiproliferative activity against cancer cells”, Biorganic & Medicinal Chemistry Letters (2006), 16: 1969-1974.

37. F.A. Harden, R.J. Quinn, P.J. Scammells, “Synthesis and Adenosine Receptor Affinity of a Series of Pyrazolo[3,4-d]pyrimidine Analogues of 1- Methylisoguanosine”, Journal of Medicinal Chemistry (1991), 34: 2892-2898.

38. G. Ege, H. Franz, Aminopyrazoles. IV (1). “Pyrazol-3- and 5-amine form 2,3-

Dihaloalkanenitriles or 3-Chloroacrylonitirles and Hydrazines”, Journal of

Heterocyclic Chemistry (1982), 19: 1267-1273

(6)

39. H. Vorbrüggen, K. Krolikiewicz, Silyation-Amination of Hydroxy N- Heterocycles, Chemische Berichte. (1984), 117: 1523-1541.

40. S. Moro, P. Braiuca, F. Deflorian, C. Ferrari, G. Pastorin, P. Cacciari, P.G.

Baraldi, K. Varani, P.A. Borea, G. Spalluto “ Combined Target-Based and Ligand-Based Drug Design Approach as Tool To Define a Novel 3D- Pharmacophore Model of Human A

3

Adenosine receptor Antagonists:

Pyrazolo[4,3-e]1,2,4-triazolo[1,5-c]pyrimidine Derivatives as a Key Study”

Journal of Medicinal Chemistry (2005), 48: 152-162.